Fig. 3: Antitumor activity of RC48 alone in mouse CRC CDX and PDX models. | Cell Death & Disease

Fig. 3: Antitumor activity of RC48 alone in mouse CRC CDX and PDX models.

From: Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer

Fig. 3

A, B Antitumor activity of RC48 in mouse COLO205 and HCT116 CDX models. BALB/c nude mice were injected s. c. with 5× 106 COLO205 or HCT116 cells. Mice bearing xenografts approximately averaged 100–150 mm3 were intravenously received saline and 10.0 mg/kg of RC48. Tumor sizes and body weight were measured twice a week. Tumor growth curve and transplanted tumor weights were assessed at the end of the experiment in mouse COLO205 (A) and HCT116 (B) CDX models. Immunofluorescence analysis (C) and immunohistochemical (D) of HER2 expression in the transplanted tumors derived from the CRC054, CRC082, CRC090 and CRC073 PDX mice. Antitumor activity (E, G, I, K) and survival benefit (F, H, J, L) of RC48 in the CRC054 (E, F), CRC082 (G, H), CRC090 (I, J) and CRC073 (K, L) PDX models. RC48 and vehicle groups were intravenously administered. Immunofluorescence images captured at 630× magnification, scale bars = 10 µm. Immunohistochemical images captured at 100× and 400× magnification, scale bars = 100 and 20 µm, respectively.

Back to article page